Market Reports

The seventh edition of this report provides an overview of the life sciences research tools (LSRT) market from 2019 to 2027. LSRT companies offer instruments, reagents and services to academic, biopharma, applied market, and (non-IVD) clinical customers. While the LSRT space includes hundreds of companies, the market is relatively consolidated, with top vendors including Agilent, Becton Dickinson, Danaher, Illumina, Merck-EMD Millipore, and (most notably) Thermo Fisher representing the majority of sales; however, mid-size players (e.g., PacBio) and smaller emerging players (e.g., Element) are often growing more rapidly, and driving innovation.

This report provides a summary of the current spatial biology market landscape, as well as a forward-looking perspective of the spatial biology market from 2024 to 2029.

The second edition of DeciBio's Clinical Oncology Biomarker Testing Market Report provides a summary of the current clinical oncology predictive and prognostic testing market landscape, as well as a forward-looking perspective of the market through 2028. Content includes a rigorous assessment of market size and growth, as well as key drivers, moderators, and trends related to predictive and prognostic biomarker testing in solid tumors.

Next Generation Sequencing (NGS)* has transformed the life sciences and diagnostics landscapes. We forecast that the ~$6.5B WW NGS manufacturer market (2023) will grow 13% p.a. to reach $9.4B in 2026

This report provides an overview of the cell therapy R&D and manufacturing market, from 2023-2028. The cell therapy market, as defined in this report, is comprised of revenue from instruments, consumables, and software sold to academic, clinical, biopharma, CDMO and CRO customers, along with service revenues generated by CDMOs and CROs.

This report provides an overview of the digital pathology market from 2023 to 2028. The digital pathology market, as defined in this report, is comprised of revenue from instruments and software sold to clinical, academic, biopharma, and CRO customers, along with service revenues generated by CROs and reference labs.

The fifth edition of this report takes a completely updated and comprehensive look at the SCA market. We assess the SCA market across 6 segments and 31 subsegments.

Liquid biopsies (LBx), which, to-date, have been used largely for genomic profiling and therapy selection, are finding new applications throughout the patient journey and within pharma research. To help predict the future state of the market, we have developed an evaluation framework to identify and assess areas of growth within the liquid biopsy market.

Technologies that profile the tumor microenvironment (TME) have become a central tool for biomarker discovery and validation, especially in the field of immuno-oncology (I/O). In addition to their utility in discovery / translational applications, technologies like multiplex tissue analysis (MTA) and AI-guided digital pathology (DP) are fast solidifying as diagnostics as well. ‍